Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald initiated coverage on Vanda Pharmaceuticals in a report on Thursday. They set an “overweight” rating and a $11.00 price target for the company.

Vanda Pharmaceuticals Price Performance

VNDA opened at $5.92 on Friday. The company has a market capitalization of $344.54 million, a PE ratio of -74.00 and a beta of 0.75. Vanda Pharmaceuticals has a fifty-two week low of $3.30 and a fifty-two week high of $6.75. The business has a 50-day moving average of $5.53 and a 200-day moving average of $4.64.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The business had revenue of $47.46 million during the quarter, compared to the consensus estimate of $48.50 million. Vanda Pharmaceuticals had a negative return on equity of 0.90% and a negative net margin of 2.75%.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of large investors have recently modified their holdings of VNDA. China Universal Asset Management Co. Ltd. boosted its holdings in Vanda Pharmaceuticals by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 5,186 shares during the last quarter. SageView Advisory Group LLC bought a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $34,000. Raymond James & Associates acquired a new stake in shares of Vanda Pharmaceuticals during the 4th quarter worth approximately $42,000. SG Americas Securities LLC bought a new stake in shares of Vanda Pharmaceuticals during the second quarter worth approximately $61,000. Finally, Mackenzie Financial Corp acquired a new position in Vanda Pharmaceuticals in the fourth quarter valued at approximately $46,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.